Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 13668-509

7 FDA label images from Torrent Pharmaceuticals Limited · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 13668-509). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure diagram of Lurasidone hydrochloride, showing the arrangement of its molecular components including rings and functional groups, with the hydrochloride (HCl) indicated separately.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A pharmacokinetic interaction chart showing the impact of different drugs on Lurasidone pharmacokinetics (PK). The chart compares fold changes in Cmax and AUC with 90% confidence intervals for several interacting drugs including Ketoconazole, Diltiazem, Rifampin, and Lithium. The x-axis represents change relative to Lurasidone alone, ranging from -4 to 4 fold change.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A scatter plot chart titled 'Impact of Lurasidone Hydrochloride on Other Drugs' showing fold changes with 90% confidence intervals for pharmacokinetic parameters (Cmax, AUC, Ctrough) of various interacting drugs including Digoxin, Midazolam, Ethinyl Estradiol, Norelgestromin, and Lithium. The x-axis represents change relative to interactive drug alone, ranging from -1.0 to 1.0.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A pharmacokinetic impact chart illustrating the fold change and 90% confidence intervals on Lurasidone hydrochloride exposure (Cmax and AUC) due to various patient factors. Factors include levels of renal impairment (mild, moderate, severe), hepatic impairment (mild, moderate, severe), gender, and race (Asian compared to Caucasian). The horizontal axis shows the change relative to reference values.*
FDA Label Image
FDA Label Image

Logo-mg (Logo mg)

FDA Label Image

60mg (Label)

60mg (Label)
Lurasidone Hydrochloride Tablets 60 mg film-coated oral tablets, packaged in a carton of 30 tablets. The label includes storage instructions (20°C to 25°C), manufacturer information (Dr. Reddy's Laboratories Limited, India), and the labeler (Torrent Pharma Inc., New Jersey). The product is identified by NDC 13668-509-30 and marked Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.